Illumina, Inc.
Illumina, Inc. Announces Stockholder Approvals at 2024 Annual Meeting
Summary
Illumina, Inc. announced that its stockholders approved several proposals at the 2024 Annual Meeting held on May 16, 2024. These include the election of eleven director nominees, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 29, 2024, and the advisory approval of the compensation paid to the Company's named executive officers. The proposals were voted on by stockholders representing 141,833,073 shares of the Company's common stock.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement